Zhen-Ao Group

Not only being a profitable organization, Zhen-Ao Group continue to invest heavily in the research and development of new products. The National 1st-Class New Drug, “Myopeptidin Cardio Injection”, is independently researched and developed by Zhen-Ao The product has already received the New Medicine certificate and been successfully story in the market; Another product of Zhen-Ao Group, “JINDERUI Capsule”, is the first healthcare supplement in China qualified by the national science and technology program;

Zhen-Ao is the world’s leading ribonucleic acid (RNA) manufacturer with over 40 years of experience in the yeast fermentation and extraction. The independently developed 5′-nucleotide project is named as “The Essential Project to Revitalize the Chinese Northeast Old industrial Base” by NDRC, and the product quality is fully in line with all international standards such as FCC (US Food Chemicals Codex), EU standards, FSANZ, Chinese GB Standard.

In China, Zhen-Ao is the pioneer performing human clinical experiments on healthcare products to affirm its actual effectiveness and safety of its nucleic acid and other healthcare supplements by working with the Shanghai Fudan University, Tongji University, and other national institutions.

Zhen-Ao also works with more than a dozen domestic and international research institutes and hundreds of scientists and scholars and build long-term cooperative relations, including the former chairman of the International Federation of Immunity, Dr. Rolf M. Zinkernagel and other 30 Nobel Prize scientists who visited Zhen-Ao providing testimonials or endorsements in the past 2 decades.  Currently, Zhen-Ao Group withholds more than 100 domestic and international patents and was named “The Pilot Unit of the National Intellectual Property” in China.